Add 2 More Reports For 20% off

Report Overview

2024

Base Year

2018-2024

Historical Year

2025-2034

Forecast Year

Epilepsy Drugs Market Size

The epilepsy drugs market was valued at USD 8193.5 million in 2024, driven by the rising prevalence of epilepsy and neurological disorders across the 8 major markets. The market is expected to grow at a CAGR of 4.40% during the forecast period of 2025-2034, with the values likely to attain USD 12025.78 million by 2034.

Epilepsy Drugs Market Outlook

  • In October 2023 a study revealed XEN1101's efficacy in reducing seizures by over 50%, offering a swift, safe, and effective treatment for focal epilepsy, potentially reshaping the landscape of epilepsy drug therapy globally.
  • In January 2024, Eisai Co., Ltd. for Fycompa® injection was approved in Japan, offering a solution for temporary inability to administer oral medication, ensuring uninterrupted epilepsy treatment.
  • The epilepsy drugs market is expected to be driven by technological advancements in diagnostic tools and treatment modalities, such as neuroimaging techniques and neuromodulation devices contributing to the market expansion.

Epilepsy Drugs Market Overview

Epilepsy is a neurological disorder characterised by recurrent seizures, affecting millions globally. The epilepsy drugs market is driven by the increasing prevalence of epilepsy, due to which the need for the development of innovative antiepileptic drugs (AEDs) by pharmaceutical companies has heightened. The market is fuelled by the escalating advancements in personalised medicine and diagnostic technologies. The rising efforts to increase awareness among people about the available treatments are also contributing to the market growth. With expanding healthcare infrastructure in developing regions, the epilepsy drugs market is poised for substantial growth.

Epilepsy Drugs Market Growth Factors

Regulatory Approvals Marking Significant Milestones in Epilepsy Treatment

In January 2024, the Japanese Ministry of Health, Labour and Welfare approved Fycompa® (perampanel), the injection form of an antiepileptic drug (AED) in Japan. The drug is an internally developed product of Eisai Co., Ltd and has been approved particularly as an alternative during situations when oral administration is temporarily impossible. Fycompa, an innovative AED discovered at Eisai’s Tsukuba Research Laboratories. It acts as a highly selective, noncompetitive AMPA receptor antagonist, aiming to mitigate neuronal hyper-excitation associated with seizures by modulating glutamate activity.

This injection offers continuity in epilepsy patients by addressing concerns of interrupted treatment during situations like surgeries. Being the sole AMPA receptor antagonist-based AED, this expansion of Fycompa’s administration route facilitates patients who are unable to use oral medication temporarily. The major focus of Eisai Co., Ltd has always been neurology, and epilepsy in particular. This development aligns with the company’s vision to enhance the quality of life for epilepsy patients. Such innovative drug developments and expanded treatment options are poised to drive the market growth, meeting the diverse needs of patients worldwide and potentially driving market expansion in the forecast period.

Surge in Drug Development Initiatives to Meet Rising the Epilepsy Drugs Market Demand

In October 2023, a groundbreaking study discovered the efficacy of an investigational medication, XEN1101, in significantly reducing seizure frequency. The medication demonstrated a reduction of more than 50 percent in some patients and even eliminated seizures overall in some patients, which is a significant advancement in epilepsy treatment. The positive findings from the phase 2b clinical trial conducted at NYU Grossman School of Medicine underscore XEN1101's potential as a swift, safe, and effective adjunctive therapy for focal epilepsy.

As XEN1101 offers a novel mechanism of action as a potassium-channel opener, it represents a significant breakthrough in epilepsy drug development. These promising results are poised to drive substantial growth in the market as patients and healthcare providers increasingly embrace this innovative treatment option. Such advancements also contribute to expanding pharmaceutical companies' market opportunities and fostering advancements in epilepsy care worldwide, fuelling the market growth.

Epilepsy Drugs Market Trends

Key Trends Impact
Increasing Prevalence of the Condition The rising prevalence of neurological disorders including epilepsy is contributing to the growth of the global epilepsy drug market.
Advancement in Drug Development  Pharmaceutical companies continue to invest in research and development in order to introduce new and improved antiepileptic drugs (AEDs). Such advancements are poised to boost market growth. These drugs aim to provide better efficacy, fewer side effects, and improved patient compliance compared to traditional treatments.
Demand for Generic Drugs The significant presence of generic drugs and latest patent expirations drive the market growth. Patent expirations of several blockbuster AEDs have led to the entry of generic versions, driving competition and increased cost-effectiveness.
Rising Awareness Around the Condition Increasing efforts to raise awareness about epilepsy and reduce the stigma associated with the condition are encouraging more individuals to seek diagnosis and treatment. This heightened awareness contributes to market growth.

Epilepsy Drugs Market Segmentation 

Market Breakup by Seizure Type
 

  • Focal Seizures
  • Generalized Seizures
  • Non-epileptic Seizures
  • Others

Market Breakup by Drug Generation

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

Market Breakup by Age Group

  • Pediatric
  • Geriatric
  • Adult

Market Breakup by Route of Administration

  • Oral
  • Nasal
  • Injectable
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Epilepsy Drugs Market Share

Focal Seizures Lead Seizure Type Segmentation

Seizure type segmentation includes focal seizures, generalized seizures, non-epileptic seizures, and others. Focal seizures lead the market segment due to their prevalence and distinct characteristics. Focal seizures require targeted treatment approaches, driving pharmaceutical companies to develop specialised medications, tailored to address the unique needs of patients experiencing focal epilepsy.

First Generation Dominates the Drug Generation Segmentation

Market share based on drug generation includes first-generation drugs, second-generation drugs, and third-generation drugs. Out of these, first-generation drugs dominate the drug generation segmentation in the global market. This can be attributed to its established efficacy, familiarity among physicians, and lower cost compared to newer generations.

Oral Route of Administration Most Preferred

Market segmentation based on the route of administration includes oral, nasal, injectable, and others.  The oral route of administration is most preferred in the global epilepsy drugs market due to its convenience, ease of use, and high patient acceptance. Oral medications offer flexible dosing regimens while providing efficient systemic drug delivery simultaneously, contributing to better seizure management and patient compliance.

Epilepsy Drugs Market Analysis by Region

Based on the regional analysis, the market covers United States, EU-4 (Germany, France, Italy, Spain)and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. The United States leads the epilepsy drugs market due to factors such as an increasing prevalence of the condition, presence of advanced healthcare infrastructure, robust research and development activities, and significant investments in innovative drug therapies. Additionally, favorable regulatory policies and strong market competition contribute to the region's dominance in the market.

Further, Japan and India are witnessing steady growth due to rising prevalence, improving healthcare infrastructure, increasing awareness, and better access to treatment options. The region is poised to witness a significant growth in the forecast period.

Leading Players in the Epilepsy Drugs Market

The key features of the market report include patent analysis, grants analysis, clinical trial analysis, and latest strategic initiatives by the leading players. The major companies in the market are as follows:

GlaxoSmithKline Plc

GlaxoSmithKline Plc (GSK) was established in 2000 and is currently headquartered in Brentford, London. It is a prominent pharmaceutical company with a significant market presence. Some of the well-known epilepsy drugs include Lamictal (Lamotrigine), Epanutin (Phenytoin) and Trobalt (Retigabine) among others.

Eisai Co., Ltd.

It is a leading pharmaceutical company based out of Japan. This company is dedicated to develop and discover several effective drugs that address the different needs of patients.

Novartis AG

It is a Swiss multinational pharmaceutical company based out of Switzerland and known for its elaborate portfolio of epilepsy drugs. Tegretol (Carbamazepine), Trileptal (Oxcarbazepine) and Sabril (Vigabatrin) are some of the examples.

Other companies in the market include UCB Pharma S.A, Sanofi, S K Biopharmaceuticals, Novel Laboratories Inc., Pfizer Inc., Neurelis, Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Sumitomo Pharma, Jazz Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd. and Alkem Laboratories Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Seizure Type
  • Drug Generation 
  • Age Group
  • Route of Administration
  • Distribution Channel 
  • Region
Breakup by Seizure Type
  • Focal Seizures
  • Generalized Seizures
  • Non-epileptic Seizures
  • Others
Breakup by Drug Generation
  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs
Breakup by Age Group
  • Pediatric
  • Geriatric
  • Adult
Breakup by Route of Administration
  • Oral
  • Nasal
  • Injectable 
  • Others
Breakup by Distribution Channel 
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • UCB Pharma S.A 
  • GlaxoSmithKline Plc 
  • Sanofi
  • S K Biopharmaceuticals
  • Eisai Co., Ltd.
  • Novartis AG
  • Novel Laboratories Inc.
  • Pfizer Inc.
  • Neurelis, Inc.
  • Dr. Reddy’s Laboratories
  • Sumitomo Pharma 
  • Jazz Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Alkem Laboratories Ltd 

Key Queries Solved in the Epilepsy Drugs Market Report

  • What was the epilepsy drugs market value in 2023?  
  • What is the epilepsy drugs market forecast outlook for 2025-2034?  
  • What are the major factors aiding the market demand?  
  • What are the major market trends? 
  • What is the market segmentation based on the seizure type?
  • What is the market breakup by drug generation?
  • How is the market segmented based on the route of administration?
  • What are segments based on distribution channels?
  • Which age group does this drug serve?
  • What are the major markets according to the EMR report? 
  • Who are the key players in the epilepsy drugs market?
  • How will the market landscape evolve in the upcoming years? 
  • What are the major drivers, opportunities, and restraints in the market? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which country is poised to lead the market share in the forecast period? 
  • Which segment has the highest impact on the market size? 
  • What is the patent landscape of the market?
  • What drugs are currently under clinical trials?
  • How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,969

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

  • Report Delivery
  • Purchase Advantages
  • Access Duration
  • Analyst Support
  • Discount on Future Updates
  • Customisation Options
  • Customisation Requests
  • Excel Data Sheet
  • Online Access
  • PDF Format
  • PPT/Word Format
  • 1 Print Allowed
  • Bulk Purchase Discounts
  • Full Report Access
  • Multi-Device Access
  • Unlimited Access
  • One-Time Purchase
  • Annual Subscription
  • 3 Years Subscription
  • Email Support
  • Phone Support
  • Up to 15 Analyst Hours
  • Up to 30 Analyst Hours
  • 5% Discount
  • 10% Discount
  • 15% Discount
  • 20% Discount
  • Basic (Up to 10%)
  • Advanced (Up to 50%)
  • Dedicated Analyst Access
  • Consultations Hours
  • Custom Data Queries
  • Custom Report Layouts
  • Tailored Custom Summaries
  • Dashboard
  • Purchase Advantages
  • Report Delivery
  • Access Duration
  • Analyst Support
  • Discount on Future Updates
  • Customisation Options
  • Customisation Requests
  • 1 Print Allowed
  • Full Report Access
  • Bulk Purchase Discounts
  • Multi-Device Access
  • PDF Format
  • Online Access
  • Excel Data Sheet
  • PPT/Word Format
  • Unlimited Access
  • One-Time Purchase
  • Annual Subscription
  • 3 Years Subscription
  • Email Support
  • Phone Support
  • Up to 15 Analyst Hours
  • Up to 30 Analyst Hours
  • 10% Discount
  • 5% Discount
  • 15% Discount
  • 20% Discount
  • Basic (Up to 10%)
  • Advanced (Up to 50%)
  • Dedicated Analyst Access
  • Consultations Hours
  • Custom Data Queries
  • Custom Report Layouts
  • Tailored Custom Summaries
  • Dashboard
  • Purchase Advantages
  • Analyst Support
  • Report Delivery
  • Access Duration
  • Customisation Options
  • Discount on Future Updates
  • Customisation Requests
  • 5 Prints Allowed
  • Full Report Access
  • Bulk Purchase Discounts
  • Limited Device Access
  • Email Support
  • Phone Support
  • Up to 15 Analyst Hours
  • Up to 30 Analyst Hours
  • PDF Format
  • Online Access
  • Excel Data Sheet
  • PPT/Word Format
  • Unlimited Access
  • One-Time Purchase
  • Annual Subscription
  • 3 Years Subscription
  • Basic (Up to 10%)
  • Advanced (Up to 50%)
  • Dedicated Analyst Access
  • Consultations Hours
  • 15% Discount
  • 5% Discount
  • 10% Discount
  • 20% Discount
  • Custom Data Queries
  • Custom Report Layouts
  • Tailored Custom Summaries
  • Dashboard
  • Report Delivery
  • Purchase Advantages
  • Customisation Options
  • Analyst Support
  • Customisation Requests
  • Access Duration
  • Discount on Future Updates
  • PDF Format
  • Excel Data Sheet
  • PPT/Word Format
  • Online Access
  • 1 Print Allowed
  • Full Report Access
  • Bulk Purchase Discounts
  • Multi-Device Access
  • Basic (Up to 10%)
  • Advanced (Up to 50%)
  • Dedicated Analyst Access
  • Consultations Hours
  • Email Support
  • Phone Support
  • Up to 15 Analyst Hours
  • Up to 30 Analyst Hours
  • Custom Data Queries
  • Custom Report Layouts
  • Tailored Custom Summaries
  • Dashboard
  • Unlimited Access
  • One-Time Purchase
  • Annual Subscription
  • 3 Years Subscription
  • 20% Discount
  • 5% Discount
  • 10% Discount
  • 15% Discount

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124